Respiratory disease companies develop therapies, diagnostics and research technologies for conditions affecting the lungs and airways. Their work supports earlier detection, improved disease monitoring and the development of treatments for acute, chronic and inherited pulmonary disorders.
This category includes companies working on:
Browse 69 UK respiratory disease companies below.
Preclinical in vitro bioassay CRO for drug discovery programmes
Cellomatics Biosciences is a UK-based contract research organisation providing bespoke preclinical in vitro bioassay services to biotechnology and pharmaceutical clients. The company specialises in cell-based assays, phenotypic screening, target validation, and toxicity profiling across oncology, immuno-oncology,…
Targeted oral drug delivery platform for cancer, CNS and respiratory disease
TRX Biosciences is a biotechnology company developing a targeted oral drug delivery platform, enabling therapies to reach specific organs, cells and tissues for cancer, central nervous system, respiratory and immune system diseases. The company's technology is licensed to partner companies for use in their own drug…
Spirometry devices and respiratory endpoint services for clinical trials
Vitalograph develops respiratory diagnostic equipment, including spirometers and pulmonary function testing systems used in healthcare, occupational health and research. The company also provides clinical trial services, with centralised collection of lung function and cardiac safety endpoint data. These services…
3D cell culture scaffolds and human tissue services for drug research
REPROCELL is a life science company combining proprietary 3D cell culture products with ex vivo human tissue testing services for the pharmaceutical industry. Its scaffold enables cells to grow in three-dimensional structures that more closely replicate in vivo tissue behaviour, supporting drug safety, efficacy, and…
Contactless respiratory monitoring and digital biomarkers for clinical trials
Albus Health is a clinical research technology company developing passive, contactless monitoring for respiratory studies and pharmaceutical trials. Its bedside Albus Home system combines acoustic and other sensors to measure nocturnal cough, breathing and environmental conditions without requiring patients to wear…
Global generics and specialty pharmaceutical manufacturer headquartered in London
Hikma Pharmaceuticals is a multinational pharmaceutical company developing, manufacturing and marketing generic, specialty and branded medicines across injectable, oral and respiratory dosage forms. The company's portfolio spans oncology, cardiovascular, respiratory, pain management and other therapeutic areas,…
Small molecule therapies for cystic fibrosis and COPD
Enterprise Therapeutics is a clinical-stage biopharmaceutical company developing novel muco-regulatory therapies for respiratory diseases. Its lead programme ETD001 is a first-in-class inhaled ENaC blocker designed to hydrate airway mucus and improve mucociliary clearance, currently in a Phase 2a trial in cystic…
Clinical gamma scintigraphy for pharmaceutical formulation evaluation
Cardiff Scintigraphics is an independent contract research company specialising in gamma scintigraphy, a clinical imaging technique using radiolabelled drug formulations to visualise and quantify in vivo drug deposition in humans. Its services support pharmaceutical and medical device companies in evaluating inhaled,…
AI imaging platform for lung and heart disease clinical trials
Qureight is a technology-driven imaging contract research organisation providing clinical data curation and AI-powered image analysis services to pharmaceutical and biotech companies. Its proprietary platform integrates CT imaging, biomarkers, and clinical metadata from complex respiratory and cardiovascular diseases,…
Non-viral gene therapy platform enabling durable nuclear DNA delivery
Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines…
Specialist pharma acquiring and developing rare disease therapeutics
Ambrose Healthcare is a UK specialist pharmaceutical company developing treatments for rare diseases and patients in hospital and specialist care settings. The company builds its pipeline through the acquisition and licensing of late-stage clinical assets with existing human safety and efficacy data, targeting…
Drug-free nasal barrier spray blocking airborne viruses and allergens
Birmingham Biotech is a University of Birmingham spin-out selling NoriZite, a drug-free nasal spray that creates a structured fluid-gel barrier in the nasal cavity for up to six hours, trapping airborne viruses, allergens and particulate pollution at the point of entry. The dual-polymer matrix formulation, developed…
Bacillus spore-based vaccines, drug delivery and probiotic therapeutics developer
SporeGen is a biotechnology company working exclusively on spore-forming Bacillus bacteria to develop vaccines, drug delivery platforms and probiotic therapeutics. The company's SporeVax platform uses bacterial spores as a vaccine delivery agent, and its SPOR-COV nasal spray, developed with a commercial partner, aims…
Broad-spectrum intranasal antivirals targeting respiratory viral infections
Pneumagen is a Scottish clinical-stage biotechnology company developing broad-spectrum intranasal antiviral therapies. Pneumagen's platform generates multivalent carbohydrate binding molecules (mCBMs) that block viral entry by binding to sialic acid residues on host epithelial cells. In 2026, Pneumagen reorganized…
Engineered macrophage cell therapy for inflammatory and fibrotic disease
Resolution Therapeutics is a clinical-stage biotech developing regenerative macrophage therapies for inflammatory and fibrotic diseases. Its platform harnesses the tissue-repairing properties of macrophages, engineering them to deliver anti-fibrotic and anti-inflammatory effects at sites of organ damage. The lead…
Programmable RNA delivery platform targeting non-hepatic tissues
Sixfold Bioscience is a biotechnology company developing a programmable RNA-based delivery platform that exploits the body's natural extracellular RNA transport pathways to direct therapeutic RNA molecules to specific non-hepatic tissues and cell types. The platform uses computationally designed chemical modifications…
Active protease biomarker assays for respiratory disease diagnostics
ProAxsis is a diagnostics company developing and supplying laboratory immunoassays and point-of-care tests for the measurement of active protease biomarkers in respiratory disease. Using patented activity-based capture technology, the company's assays quantify neutrophil elastase and proteinase 3 as indicators of…
Preclinical therapeutic company targeting tissue fibrosis in allergic asthma
Fibraxis is a preclinical-stage biotechnology company developing a therapeutic for allergic asthma that targets tissue fibrosis in the lung. Spun out of Aston University and supported by SPARK The Midlands, the company builds on research into pericytes, the mesenchymal cells implicated in airway scarring and…
Aerosol technology for inhaled drug formulation development
Microsol is a Bristol-based technology company developing advanced measurement and computational tools for aerosol characterisation in respiratory drug delivery. Its platform combines single-particle measurement capabilities with predictive simulations to analyse evaporation kinetics, hygroscopicity, and morphology…
Multiomics blood-based platform for early-stage cancer detection
Freenome is a biotechnology company developing blood-based early cancer detection tests using a multiomics platform that combines tumour and non-tumour biological signals with machine learning. The UK subsidiary, based in Nottingham, holds the autoantibody immunodiagnostic technology and cancer detection pipeline…